Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know.
Bristol-Myers Squibb beat analysts’ revenue expectations by 6.6% last quarter, reporting revenues of $12.34 billion, up 7.5% year on year. It was a mixed quarter for the company, with a solid beat of analysts’ EPS estimates but a significant miss of analysts’ full-year EPS guidance estimates.
Is Bristol-Myers Squibb a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Bristol-Myers Squibb’s revenue to decline 8.9% year on year to $10.81 billion, a reversal from the 4.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.50 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bristol-Myers Squibb has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Bristol-Myers Squibb’s peers in the pharmaceuticals segment, only Johnson & Johnson has reported results so far. It beat analysts’ revenue estimates by 1.5%, delivering year-on-year sales growth of 2.4%. The stock price was unchanged following the results.
Read our full analysis of Johnson & Johnson’s earnings results here.
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.